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studies, see Kehoe 2018 for review), but existing RCTs, where AD was the targeted outcome,
are not yet completed [26] [27] [28] . Studies of AHT drugs in people with cardiovascular morbidities have not reported cross-class differences in relation to secondary investigations on cognition and dementia [3, 7, 8, 12, 19, 29, 30] .
Despite important advances in the potential RAS-AD link, and efforts to enroll minorities in clinical trials, there have been limited population-based investigations on these relationships in samples with substantial representation of women and racial/ethnic minorities, providing little evidence on cross-class differences for specific subpopulations that could inform the generalizability of various treatments on AD risk. Investigations of large datasets can help close this research gap. It is well documented that RAS-acting agents function differently in African Americans compared to Caucasians, with higher endogenous sodium and lower renin levels for African Americans. Because African Americans are at higher risk for AD, and it is unknown whether there are racial differences in brain RAS function, it is important to address these mechanistic questions in all ethnic groups. Estrogen also has a role in RAS-mediated effects on AD pathology, while differences across race in genetic coding for drug-metabolizing enzymes and transporters suggest that these effects could vary across sex and race/ethnicity [31, 32] . Some medications for chronic conditions, such as statins, have differential associations with AD risk across subpopulations, but such relationships have not been similarly examined for RAS-acting and non-RAS-acting AHTs [33] .
To our knowledge, this is the first study to examine AD risk reduction among six different anti-hypertensive medications including both RAS-acting and non-RAS-acting AHTs in African American, Hispanic, and Caucasian men and women. While the different AHTs are similarly effective in reducing blood pressure, differences in their association with AD risk for black, non-Hispanic white, and white men and women could point to effects independent of blood pressure and have implications for clinicians, particularly those who serve minority populations [34, 35] . We used longitudinal claims data from 2007-2013 for a representative sample of fee-for-service Medicare beneficiaries ages 67 and older to analyze the association of RAS-acting AHT use compared to non-RAS-acting AHT use and AD onset. We examined differences within RAS-acting AHTs by comparing ACEIs and ARBs, and whether associations vary by sex and race/ethnicity in multivariable regressions that control for age, sex, race, education, income, comorbidities, health care utilization tendencies, and statin use.
Methods

Data
We examined the medical and pharmacy claims of a random 20% sample of Medicare beneficiaries enrolled in traditional Medicare (fee-for-service) from 2007 to 2013. The enrollment file includes beneficiary characteristics, which can be linked with claims from Medicare Parts A, B, and D. Part D claims include key elements related to prescription drug events, while Parts A and B claims capture inpatient and outpatient encounters, including detailed diagnosis and procedure codes (International Classification of Diseases, Ninth Revision (ICD-9)). These data were further supplemented with claims histories from the Chronic Conditions Warehouse. Institutional review board approval was granted by the University of Southern California University Park IRB, which granted a waiver of participant consent under 45 CFR 46.116(d) .
Study sample
The study sample consisted of Medicare beneficiaries age 67 and older. We required observation of each individual for a minimum of three years with consecutive fee-for-service enrollment, Part D enrollment, and no death. Individuals were required to have used at least one AHT class for two consecutive years, no prior AD diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine. We required an AD index diagnosis (ICD-9 331.0) to be verified with either a second AD diagnosis code or 'dementia specified elsewhere' diagnosis code in a subsequent claim within the study period (2009) (2010) (2011) (2012) (2013) . The analytic sample consisted of 1,343,334 unique beneficiaries, followed for a total of 4,215,338 person-years (2,820,575 for females, 3,501,668 for non-Hispanic whites, 295,521 for blacks, 230,887 for Hispanics, and 187,262 for Asian, Native American, or unknown race/ethnicity). Table 1 shows the characteristics of the analytic sample.
Measuring AHT exposure
We identified AHT use by selecting Part D claims (2007) (2008) (2009) (2010) (2011) (2012) (2013) for the following classes: angiotensin-converting enzyme inhibitors (ACEI), angiotensin-II receptor blockers (ARB), betablockers (BBL), calcium channel blockers (CCB), loop diuretics (LDs), and thiazide-like diuretics (TDs). We defined an AHT user as any individual with 90 days supply and at least two drug claims in a year for two consecutive years. This threshold was chosen as the minimum necessary to ensure regular use of the drug during the exposure period, but other definitions were used in sensitivity analyses (see Limitations, below). Combination use of multiple AHTs is relatively common; Fig 1 shows the percent of the study sample using each of the AHT drug classes in 2013. Participants were classified as RAS-acting AHT users if they were taking a RAS AHT drug alone, or in combination with another AHT.
Study design
We compared onset of AD for RAS-acting AHT drug users to those using only non-RAS-acting AHTs, using index date of AD diagnosis. Measurement error in the timing of AD diagnosis does is unlikely to bias our results because the same error exists for the AHT users in both the exposure and comparator groups. To mitigate concern that imminent AD onset could lead to poor adherence or discontinuation of AHT use, we designated years t-1 and t-2 as AHT exposure years, prior to assessing AD risk in year t. In addition to analyses that define RAS use as the aggregate of ACEI and ARB, we also compared the independent effects of ACEI and ARB use to non-RAS-acting AHT use. Sex and race/ethnicity specific analyses use only members of the same subgroup as the comparison group, thus estimated differences in association with type of AHT is attributed to drug class and not due to (unobserved) differences across race/ ethnicity.
Statistical analyses
We examined the association of RAS AHT use (in years Medicaid and Medicare Services-Hierarchical Condition Category (CMS-HCC), an index based on health status from diagnostic data and demographics, in which higher numbers indicate worse health. The CMS uses this index to predict health expenditures in the next year, and it correlates highly with mortality [36] . We used years since hypertension diagnosis, as measured by the Chronic Conditions Warehouse (CCW), to control for unobserved AHT use in the years prior to Medicare Part D enrollment. Race/ethnicity was determined with the beneficiary race code in CMS enrollment data, and with the application of a name-based identification algorithm from the Research Triangle Institute [37] . Sex and race/ethnicity specific analyses use only members of the same subgroup as the comparator. Standard errors were clustered at the county level. We ran analyses for the sample as a whole, as well as for each sex-race/ethnicity subgroup. Table 1 shows the sample characteristics by type of AHT. The average age of RAS users is 78.0 years, while those using the other four AHTs averaged 78.4 years. RAS users had an average comorbidity score of 1.31 and averaged 9.3 physician visits per year, compared to 1.37 and 9.5 for users of the other four non-RAS-acting AHTs. Comorbidity prevalence across the two groups was: acute myocardial infarction (7% for both groups), atrial fibrillation (18% for RAS users, 21% for other non-RAS-acting AHT users), diabetes (47% for RAS users, 44% for non-RAS-acting AHT users), stroke (17% for RAS users, 18% for non-RAS-acting AHT users), hyperlipidemia (89% for RAS users, 88% for non-RAS-acting AHT users), and non-AD dementia (8% for both groups). Clinical guidelines currently recommend both RAS-acting and non-RAS-acting AHTs as first line therapies for hypertension, in the nonblack hypertensive population, including those with diabetes. Notably, 2017 blood pressure guidelines advise that initial AHT treatment for African Americans should include a TD or CCB instead of a RAS-acting AHT [35] . During the years 2009-2013, 0.97% of AHT users were diagnosed with AD each year ( Table 1) . RAS-acting AHT users had statistically significantly lower rates of AD incidence (0.88%), compared to non-RAS-acting AHT users (0.97%). ARB users had a statistically significantly lower incidence rate (0.81%), compared to ACEI users (0.92%). For comparison, in Medicare samples without drug use or death restrictions, we find AD incidence rates between 2.0% and 2.7%, depending on how restrictive we are in determining who is at risk. The Alzheimer's Association estimates that the general population ages 65 and older had an AD incidence rate of 1.15% in 2013. [38, 39] The odds ratios (OR) from multivariable logistic regressions of AD risk and RAS-acting AHT use are depicted in Fig 2, with odds ratios, p-values, and confidence intervals provided in S1 Table. Each OR is the result from a separate regression, which compares RAS AHT users to non-RAS AHT users in the same sex-race/ethnicity subgroup. 
Results
Discussion
We analyzed the association between use of RAS-acting AHTs and AD onset across sex and race/ethnicity, and allowed for the possible separate biological roles of ACEIs and ARBs as has been suggested for AD [18, 40, 41] . While there is some evidence of risk reduction from RASacting AHTs, most of that association is driven by ARBs rather than ACEI use.
Why RAS AHTs may provide benefit in AD, compared to other AHTs, is potentially driven by a combination of genetic, pre-clinical, epidemiological, and a limited number of directly relevant clinical factors [18, 42, 43] . Multiple components of the RAS are associated with changes to amyloid-beta (Aβ) and tau levels in both pre-clinical models as well as human postmortem studies [18, 24, [44] [45] [46] . Furthermore, RAS-acting AHTs have been reported to reduce the incidence of AD and slow the progression from MCI to AD in African Americans and Caucasians, leading to new studies whereby RAS-acting drugs are being tested as interventions for AD [12, 18, 19, 40, 41, 47] .
Both ARBs and ACEIs were designed to treat hypertension by reducing signaling of the angiotensin II peptide hormone via the angiotensin II type-1 receptor (AT1R), but they differ in how they achieve the reduction in angiotensin II, and may differentially affect processes related to AD [3, 27] . ACEIs inhibit the activity of angiotensin I-converting enzyme (ACE) and thus the formation of angiotensin II. ARBs do not directly interfere with angiotensin II production, but instead block the binding and signaling of angiotensin II via its receptor AT1R. However, ACE has also been reported to degrade Aβ, and it has therefore been suggested that ACEIs may adversely alter ACE-mediated degradation of Aβ in the brain [27] . This would likely be disadvantageous, since Aβ is thought to be a significant factor in the development and pathology of AD. Yet ARBs could selectively inhibit the detrimental effects of angiotensin II without inhibiting ACE.
The potential involvement of the RAS in AD is particularly important in the African American population, because of differences in how the RAS functions in this ethnic group. The peripheral RAS functions differently between African Americans and Caucasians, with higher endogenous sodium and lower renin levels for African Americans. It is less clear, however, if in the brain, RAS functions differently between groups, but data suggest that AD related brain benefits via RAS therapy are applicable to both groups [12] . Additionally, both AD incidence and prevalence are higher in African Americans compared to Caucasians [48] . These results are especially important because the US population aged 65 years and older is projected to more than double by 2060 [49] . Over the same time period, the African American population is expected to grow from 14% to 18% of the total population, while the single race nonHispanic white population is expected to decrease from 62% to 44% [50] . African Americans are also more likely to be hypertensive, an independent risk factor for AD, leading to an overall Anti-hypertensive medication classes and Alzheimer's disease risk less healthy population. Thus, understanding the potentially beneficial effects of certain RASacting AHTs in this high-risk population is of great importance.
The results show that RAS AHTs are associated with lower AD risk for males (OR = 0.931, CI: 0.895-0.969) than females (OR = 0.985, CI: 0.963-1.007). In models that separated ACEIs and ARBs, the level of risk lowering in the ARBs was greater for males (OR = 0.834, CI: 0.788-0.884) than females (OR = 0.941, CI: 0.913-0.969). These disparities could relate to interactions that exist between estrogen and the RAS throughout life that may also have a bearing on late life RAS-mediated changes to AD pathology [32] . It is also possible that the beneficial effects of RAS-acting AHTs would be more evident in younger and middle aged women who are nearer the menopausal transition, while RAS related benefits for men may extend across the lifespan. It is worth noting that RAS-acting antihypertensives are contraindicated during the second and third trimesters of pregnancy because of increased risk of fetal renal damage, so women taking RAS therapy would be prescribed different antihypertensives during this time. It is therefore possible that women who are planning to become pregnant change their antihypertensive regimen and are likely to stay on non-RAS medications after pregnancy. As such, the RAS benefits favoring men may reflect longer exposure times from RAS-acting medications favoring longer brain related protection.
Unlike the other population subgroups, there was no benefit on average of ARBs for Hispanic females (OR = 0.996, CI: 0.911-1.088). It is not clear why there was no benefit in this population, particularly when there is high prevalence of RAS-associated obesity, metabolic disorders, and hypertension, all of which are risk factors for AD [51] . Yet, very little is known regarding whether there are ethnic differences in the RAS in Hispanics, in the same way that differences exist between Caucasians and African Americans. Unlike Caucasians and African Americans, there are currently no widely disseminated guidelines for treating hypertension in Hispanic populations, likely because many clinical studies have not included Hispanic populations and there is little literature describing RAS function among Hispanics [51] [52] [53] .
While there is now some evidence of long term effects of midlife hypertension management on improved late-life cognition, our study focuses on the role of relatively recent hypertension treatment for older adults [54] . This approach is driven by evidence suggesting that there are also short term effects of AHT treatment on cognition, especially for ARBs [19, 55] . Of note, our results showing cognitive preservation are likely the result of multiple RAS-related benefits, in addition to the medications' direct action on tau and amyloid-β. Mechanisms include improved or preserved cerebral blood flow, anti-inflammatory effects, and pro-cholinergic effects [14, 25, 56, 57] . We have also reported that RAS-acting medications, used for only four months, were able to cross the blood brain barrier and alter ACE activity and levels in the brain in middle aged individuals with a parental history of AD [58] . This suggests that while the brain and peripheral RAS operate largely independently, so long as the blood brain barrier is not compromised, RAS-acting medications are able to change components of the brain RAS in a relatively short amount of time.
Limitations
The Medicare claims data provide an excellent setting for this type of study, with large and diverse samples, and no recall bias. There are, however, several limitations to these data, including the possibility that AHT use and/or AD are measured imprecisely. For example, switching between classes of AHT within a year would allow someone to be marked as a user of multiple classes within a year, or have some uncaptured use. This behavior, however, would lessen the observed differences across classes, and therefore bias our results toward zero. To address concerns about the effects of AHT use that occurred prior to observation in 2007, we control for years since hypertension diagnosis, which is observed as far back as 1999 if continuously enrolled in FFS Medicare. We are also concerned that AD diagnosis practices are imprecise, which can lead to measurement error in the timing of diagnosis, and across types of dementias. To address these problems, we require that AD diagnoses are verified on subsequent claims. Additionally, this type of measurement error would only be a problem if it varied systematically across AHT classes, which seems implausible. Another limitation of the claims data is that we are unable to control for apolipoprotein E (ApoE) status given current clinical practice does not test for ApoE.
When comparing users of multiple classes of AHTs, it is possible that unobserved patient characteristics could sort users across classes, and also affect AD risk differences. Few observable differences were found (Table 1 ) and we include a detailed set of control variables such as, age, comorbid conditions, zip code level high school graduation rates, and zip-code level median income in our estimation models. Additionally, all six classes of AHTs have generic versions available within the years of our study, making them inexpensive for our sample of Medicare Part D beneficiaries, and therefore diminishing the potential for socioeconomic differences to influence drug choices. Ideally, we would be able to control for blood pressure, so that we could precisely identify the role of AHT classes, net of blood pressure effects. Since we cannot observe blood pressure, we include controls for comorbidities that serve as proxies for extreme blood pressure: acute myocardial infarction, atrial fibrillation, and stroke.
Differences in the guidelines for hypertension treatment across ethnic groups might also cause systematic variation in the characteristics of AHT users across class. However, any such treatment selection patterns would be held constant in our analyses of population subgroups, which only compare each sex and race/ethnicity to members of the same group. Additionally, Table 1 shows the characteristics of the different AHT use groups, and gives empirical evidence that these groups have similar underlying characteristics, suggesting that protectiveness differences across class are not driven by patient selection.
The study period investigated here coincided with rapid growth in enrollment in Medicare Advantage plans. This selective attrition would only potentially influence the results if users of a particular AHT class were more or less likely to join a Medicare Advantage plan, which is likely implausible. However, we conducted sensitivity analyses on a sample restricted to subjects that survived and were observed through to the end of 2013 (no movement between feefor-service and Medicare Advantage plans). The results of these analyses are featured in S3 and S4 Tables, and show no meaningful differences from the main results.
As shown in Fig 1, use of combinations of AHTs within a single year is common. For this reason, differential combination patterns between ACEIs and ARBs could be responsible for the relatively greater AD protection from ARB use. Fig 1 shows relatively similar combination use patterns for these two classes, except for TD use that is more common for ARB users than ACEI users. Ordinarily there are certain considerations, due to drug interactions, of what types of diuretics can be taken with RAS-acting AHTs. As such, potassium sparing diuretics (which TDs are not) do not tend to be given together with RAS-acting drugs to reduce the risk of hyperkalemia [59] . To ensure that the results are not driven by the differences in TD use, we conducted a sensitivity analysis in a sample that dropped all observations with use of TDs. These results (S5 and S6 Tables) show small changes in the magnitudes of some of the estimates, but the not in the statistical significance and are consistent with the main results.
Other robustness checks included varying the definition of user, with thresholds at 180 (S7 and S8 Tables) and 270 (S9 and S10 Tables) days of use, instead of 90. These adjustments require more adherent use of all the AHTs, including the non-RAS-acting classes in our comparison group. These results show that the differences between ACEIs and ARBs, and across sex, are robust to the definition of user. Differences between RAS and non-RAS drugs for white males were no longer statistically different with a more restrictive definition of user (270 days).
Conclusion
Our findings suggest that the use of certain AHTs could provide benefits in addition to those ordinarily associated with blood pressure reductions. ARBs may be more protective against AD than ACEIs, and thus could reduce some of the burden of AD for the afflicted individuals, their caregivers, and the health system as a whole. The burden of AD is multifaceted and disparate, and even small delays in AD onset can lead to disproportionately larger reductions in this large and growing burden. For example, if it were possible to achieve a one year delay in the onset of AD, this would lead to a reduction in the U.S. population ages 70 and older with AD in 2050 by 14% and savings of $219 billion in medical and caregiving costs in 2050 [2] . A fiveyear delay in AD onset would reduce the U.S. population with AD in 2050 by 41% [2] .
Supporting information S1 Table. Odds ratios (with 95% CI) of AD incidence associated with use of RAS AHTs, relative to non-RAS users. Each OR is the result from a separate regression, which compares RAS AHT users to non-RAS AHT users in the same sex-race/ethnicity subgroup. , beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics). Each pair of ORs (for ACEI and ARB) represents results from a separate regression, which compares ACEI and ARB users to non-RAS users in the same sex-race/ethnicity subgroup. Users defined as those with 90 possession days and 2 claims in year t-1 and year t-2. Sample restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior AD diagnoses, no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine, and no attrition through 2013 (except for AD diagnosis). RAS (renin angiotensin system) acting drugs are ACEIs and ARBs. Controls are age, age squared, sex, race, education, income quartiles, statin use (t-1), years since hypertension diagnosis, HCC comorbidity index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction, stroke, and hyperlipidemia. Standard errors are clustered at the county level. (DOCX) S5 Table. Odds ratios (with 95% CI) of AD incidence associated with use of RAS AHTs, relative to non-RAS users, in sample with no use of thiazide-like diuretics. Logistic regression results with sample of 2009-2013 Medicare enrollees with use of antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics). Each OR is the result from a separate regression, which compares RAS AHT users to non-RAS AHT users in the same sex-race/ethnicity subgroup. Users defined as those with 90 possession days and 2 claims in year t-1 and year t-2. Sample restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior AD diagnoses, no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine, and no use of thiazide-like diuretics. RAS (renin angiotensin system) acting drugs are ACEIs and ARBs. Controls are age, age squared, sex, race, education, income quartiles, statin use (t-1), years since hypertension diagnosis, HCC comorbidity index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction, stroke, and hyperlipidemia. Standard errors are clustered at the county level. (DOCX) S6 Table. Odds ratios (with 95% CI) of AD incidence associated with use of ACEI and ARBs, relative to non-RAS users, in sample with no use of thiazide-like diuretics. Logistic regression results with sample of 2009-2013 Medicare enrollees with use of antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics). Each pair of ORs (for ACEI and ARB) represents results from a separate regression, which compares ACEI and ARB users to non-RAS users in the same sex-race/ethnicity subgroup. Users defined as those with 90 possession days and 2 claims in year t-1 and year t-2. Sample restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior AD diagnoses, no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine, and no use of thiazide-like diuretics. RAS (renin angiotensin system) acting drugs are ACEIs and ARBs. Controls are age, age squared, sex, race, education, income quartiles, statin use (t-1), years since hypertension diagnosis, HCC comorbidity index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction, stroke, and hyperlipidemia. Standard errors are clustered at the county level. 
